ecancer

Part 7: Similarities and Differences

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

5 Sep 2023

Part 8: How PARP inhibitors are being used now

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

5 Sep 2023

Part 9: What PARP inhibitors mean for the future and what to look out for

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

5 Sep 2023

The case for investing in women's cancers in Asia Pacific

Dr Heather White - Executive Director, TogetHER for Health

4 Sep 2023

Nigeria solidarity support fund and the annual youth engagement campaign on HPV

Dr Fejiro Chinye-Nwoko - CEO, Nigeria Solidarity Support Fund, Lagos, Nigeria

25 Aug 2023

Psilocybin-assisted psychotherapy for cancer-related anxiety and depression

Dr Moran Amit - The University of Texas MD Anderson Cancer Center, Houston, USA

23 Aug 2023

AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours

Dr Linda Malkas - City of Hope, Duarte, USA

8 Aug 2023

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

4 Aug 2023

Sudan: Conflict, cancer care, and ripple effects on the region

Dr Nazik Hammad - University of Toronto, Toronto, Canada

19 Jul 2023

Geriatric oncology in resource-limited settings

Dr Enrique Soto Perez de Celis - National Institute of Medical Sciences, Mexico City, Mexico

18 Jul 2023

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

7 Jul 2023

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

6 Jun 2023

More from ecancer